華熙生物(688363.SH):公司是國內較早認識到中試環節重要性並率先建設合成生物中試轉化平台的企業
格隆匯5月24日丨華熙生物(688363.SH)在投資者互動平台表示,作為國內較早佈局合成生物的企業,公司已經構建了一條覆蓋“研發創新、中試及產業轉化、市場轉化”的合成生物綠色製造全產業鏈,擁有從“基因編輯、菌種改造、細胞工程創造,到中試及產業轉化、再到市場轉化”的全鏈條能力。同時,公司也是國內較早認識到中試環節重要性並率先建設合成生物中試轉化平台的企業。2023年公司利用包括合成生物學研發平台在內的六大研發平台,共上市9種生物活性物原料新產品:其中,3款醫藥/醫療器械級原料產品,4款個人護理原料產品和2款食品級原料產品。同時,微交聯透明質酸粉末產品HyacrossTL200、陽離子HA、酶法唾液酸、多聚寡核苷酸、GABA織物整理劑、蛹蟲草發酵液、益生菌組合發酵物等已完成試產,紅景天苷、肌肽、人乳寡糖完成中試。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.